[Clinical characteristics and gene analysis of SYNGAP1-related epilepsy in children]

X J Tian1, F Fang1, C H Ding1

  • 1Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.

Insights

SYNGAP1-related epilepsy in children presents with early-onset seizures, predominantly eyelid myoclonia, and often includes developmental delays. Valproate shows effectiveness, though some cases remain intractable.

Area of Science:

  • Pediatric Neurology
  • Clinical Genetics
  • Epileptology

Background:

  • SYNGAP1 gene variants are increasingly recognized as a cause of developmental and epileptic encephalopathies.
  • Understanding the specific clinical phenotype associated with SYNGAP1 mutations is crucial for diagnosis and management.

Purpose of the Study:

  • To delineate the clinical characteristics, seizure types, EEG findings, and treatment responses in children with SYNGAP1-related epilepsy.
  • To evaluate the efficacy of antiepileptic drugs, particularly valproate, in this patient cohort.

Main Methods:

  • Retrospective analysis of clinical data from 13 pediatric patients with genetically confirmed SYNGAP1 epilepsy.
  • Review of seizure types, electroencephalogram (EEG) findings, neuroimaging, genetic variants, and treatment outcomes.
  • Follow-up data collected over a defined period to assess seizure control and developmental progress.

Main Results:

  • Early seizure onset (median 2 years) with diverse seizure types, including eyelid myoclonia with absence, myoclonic, and atypical absence seizures.
  • Developmental retardation, primarily affecting speech, was present in all patients (moderate to severe in most).
  • Valproate demonstrated significant efficacy in 9 out of 12 treated patients, while levetiracetam showed partial effectiveness in 3 out of 5 cases.

Conclusions:

  • SYNGAP1-related epilepsy is characterized by early onset, varied seizure semiologies, and significant developmental impairment, particularly speech delay.
  • Valproate is an effective first-line treatment for many, but intractable epilepsy can occur.
  • Genetic testing for SYNGAP1 variants is important for children with unexplained early-onset epilepsy and developmental delay.